TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Immunovant ( (IMVT) ) is now available.
On November 21, 2025, Michael Geffner, M.D., M.B.A., stepped down as Chief Medical Officer of Immunovant, Inc. as part of the company’s restructuring of its R&D leadership under CEO Eric Venker, M.D., PharmD. The company has arranged a Separation Agreement with Dr. Geffner, which includes severance benefits and a consulting period until April 30, 2026, during which his equity awards will continue to vest. This transition is part of Immunovant’s strategic efforts to streamline its leadership and potentially enhance its market positioning.
The most recent analyst rating on (IMVT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Immunovant stock, see the IMVT Stock Forecast page.
Spark’s Take on IMVT Stock
According to Spark, TipRanks’ AI Analyst, IMVT is a Neutral.
Immunovant’s stock score is primarily impacted by substantial financial weaknesses, including ongoing losses and cash flow issues. Technical indicators are bearish, further weighing on the stock’s attractiveness. However, recent positive clinical trial results and leadership changes provide some optimism, potentially strengthening the company’s pipeline and long-term prospects.
To see Spark’s full report on IMVT stock, click here.
More about Immunovant
Immunovant, Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for autoimmune diseases.
Average Trading Volume: 1,758,672
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.06B
For detailed information about IMVT stock, go to TipRanks’ Stock Analysis page.